Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers.
cascade impactor
critical quality attributes
delivered dose
empirical correlations
fine particle dose
mean dissolution time
metered dose inhalers
mouth-throat models
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
07 12 2021
07 12 2021
Historique:
received:
12
04
2021
accepted:
17
08
2021
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
5
4
2022
Statut:
epublish
Résumé
The therapeutic benefits of metered dose inhalers (MDIs) in pulmonary disorders are mainly driven by aerosol performance, which depends on formulation variables (drug and excipients), device design, and patient interactions. The present study provides a comprehensive investigation to better understand the effect of formulation variables on mometasone furoate (MF) suspension-based MDI product performance. The effects of MF particle size (volume median diameter; X
Identifiants
pubmed: 34874508
doi: 10.1208/s12248-021-00638-1
pii: 10.1208/s12248-021-00638-1
pmc: PMC10662261
mid: NIHMS1942909
doi:
Substances chimiques
Aerosols
0
Suspensions
0
Mometasone Furoate
04201GDN4R
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Subventions
Organisme : FDA HHS
ID : U01 FD004943
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Références
Mol Pharm. 2015 Aug 3;12(8):2618-24
pubmed: 26091361
AAPS PharmSciTech. 2015 Feb;16(1):192-201
pubmed: 25273026
Pharm Res. 2010 May;27(5):786-95
pubmed: 20229134
Br J Clin Pharmacol. 2005 Dec;60(6):605-10
pubmed: 16305584
Thorax. 1995 Jul;50(7):746-9
pubmed: 7570408
AAPS PharmSciTech. 2014 Apr;15(2):434-55
pubmed: 24452499
Biomed Res Int. 2013;2013:574310
pubmed: 23984381
J Aerosol Med Pulm Drug Deliv. 2014 Jun;27(3):193-9
pubmed: 23837901
AAPS PharmSciTech. 2019 Feb 27;20(3):130
pubmed: 30815748
Chest. 2002 Aug;122(2):510-6
pubmed: 12171824
Respir Care. 2005 Sep;50(9):1177-90
pubmed: 16122401
Drug Dev Ind Pharm. 2013 Nov;39(11):1625-37
pubmed: 24087854
J Aerosol Med Pulm Drug Deliv. 2013 Dec;26(6):355-69
pubmed: 23421897
J Drug Target. 2006 Dec;14(10):680-6
pubmed: 17162737
Adv Drug Deliv Rev. 2003 Jul 18;55(7):807-28
pubmed: 12842602
Drug Dev Ind Pharm. 2004 Aug;30(7):705-14
pubmed: 15491048
Int J Pharm. 2017 Nov 30;533(2):346-356
pubmed: 28579542
J Asthma. 1998;35(3):273-9
pubmed: 9661680
J Aerosol Med Pulm Drug Deliv. 2018 Dec;31(6):358-371
pubmed: 29878859
Eur J Pharm Sci. 1999 Jan;7(2):137-44
pubmed: 9845798
AAPS J. 2017 Sep;19(5):1396-1410
pubmed: 28593514
Pharm Res. 1995 Feb;12(2):231-6
pubmed: 7784338
AAPS PharmSciTech. 2018 Jul;19(5):2335-2345
pubmed: 29858973
Int J Pharm. 2013 Oct 15;455(1-2):57-65
pubmed: 23911912
J Aerosol Med. 2005 Winter;18(4):379-85
pubmed: 16379614
Respir Med. 2010 Sep;104(9):1237-45
pubmed: 20472415
J Clin Pharmacol. 1997 Oct;37(10):881-92
pubmed: 9505979
Int J Pharm. 1999 Sep 10;186(1):13-30
pubmed: 10469920
Int J Pharm. 2017 Aug 7;528(1-2):360-371
pubmed: 28599855
Drug Dev Ind Pharm. 2015 May;41(5):737-43
pubmed: 24641447